SY0351, a THZ1-based inhibitor with improved selectivity towards CDK7 showed efficient antitumor effects in multiple AML xenograft models [29] and extended previous views of CDK7 as a direct activator for the CDK-activating kinase for CDKs9/12 and 13 [30]. The gene discussed is CDK7; the disease is acute myeloid leukemia.